Our Team

The Fidelis Pharmaceuticals Team of Experts

Our leadership team possesses a wealth of experience in developing innovative, effective pharmaceutical solutions for veterinary medicine.

The Fidelis team applies specialized product development and manufacturing expertise to formulate reliable, cGMP-quality products uniquely suited to meet veterinary needs.

Michael Wells
Executive Chairman

Michael Wells serves as the Executive Chairman for Fidelis Pharmaceuticals. He has had a long and distinguished career as an entrepreneur and an investor in start-up healthcare companies. In addition to his role at Fidelis, he is the founding Managing Director of Princeton Biopharma Capital Partners, a firm he created in 2010 for the purpose of providing growth capital to pharmaceutical and medical device companies. Prior to creating this company, he was the founder and CEO of Aton Pharma, a pharmaceutical company focused on rare diseases. For his part in creating and growing this company, he was named an Ernst & Young Entrepreneur of the Year in 2009, and in 2010 the company was acquired by Valeant Pharmaceuticals for $330 million. Michael has played a role in the formation of five companies and frequently mentors aspiring entrepreneurs. His career began at Merck & Co., where he held a range of sales and marketing positions over eight years.

Michael earned Bachelor of Science and Master of Science degrees from the University of Pittsburgh, in addition to an MBA from The Wharton School. He serves on the Fidelis Board of Directors, as well as those of Covis Pharma SARL, Valeo Pharmaceuticals, and PhotoSonix Medical. He is a Trustee at the University of Pittsburgh.

Clay Wilson, MD, JD
Founder; Executive Vice President, Commercial Development

Clay Wilson, MD, JD, is the founder of Fidelis Pharmaceuticals and now serves as Executive Vice President for Commercial Development. He is a seasoned medical industry executive, a physician by training, and a patent attorney. His business background includes securities analyst positions covering biotech and medical devices for Wall Street firms Needham and Smith Barney/Citigroup. Clay has also held executive roles in business development at both Johnson & Johnson and Bristol-Myers Squibb and has served as an investment banking advisor in the healthcare group at the accounting firm KPMG.

Steven Leary, DVM
Chief Medical Officer

Steven Leary, DVM, DACLAM, serves as Chief Medical Officer with Fidelis Pharmaceuticals. He received his DVM from Iowa State University and postdoctoral training in laboratory animal medicine and comparative pathology from Johns Hopkins University. Dr. Leary has 40 years’ experience, including serving as director at the University of Alabama at Birmingham and Washington University in St. Louis. He served on the AAALAC Council, as president of ACLAM, and as chair of the AVMA Animal Welfare Committee and Panels on Euthanasia, Humane Slaughter, and Depopulation. He is past recipient of the ISU Stange Award, Charles River Prize, and AALAS Griffin and Nathan R. Brewer awards.

Eric Schreiber
Vice President of Sales and Marketing

Eric Schreiber is VP of Sales and Marketing for Fidelis Pharmaceuticals. Eric has broad animal health commercialization experience, having launched more than 20 brands in his career, including pain management products for small animals.  He has worked for manufacturers Pfizer Animal Health and Wyeth Pharmaceuticals, as well as for ad agencies Saatchi & Saatchi and Ogilvy.  Eric graduated from Bucknell University and did graduate work at University of Richmond and The Wharton School.